問卷

TPIDB > Search Result > Study Site

Study Site



National Taiwan University Hospital

  • 1,343

    Total Beds

  • 801

    Total Doctors

  • n123987ctc@gmail.com
  • Hsin-Pin Tu
  • 06-2353535#4691
  • 704Tainan CityTainan NorthNo.138,Sheng Li Road,Tainan, Taiwan

篩選

List

1593Cases

2016-07-05 - 2020-07-05

Phase II

ONO-4538 Phase II/III Study Multicenter, Open-Label, Randomized Study in Patients with Unresectable Advanced or Recurrent Gastric Cancer
  • Condition/Disease

    Advanced or Recurrent Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
12Sites

Terminated10Sites

2016-09-01 - 2021-11-30

Phase III

A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected Treatment-naïve Adults adults
  • Condition/Disease

    Infection, Human Immunodeficiency Virus HIV Infections

  • Test Drug

    Dolutegravir(DTG),Lamivudine(3TC).Tenofovir(TDF )/emtricitabine(FTC)

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2014-11-01 - 2022-02-28

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
  • Condition/Disease

    Pancreatic Adenocarcinoma

  • Test Drug

    nab-Paclitaxel

Participate Sites
6Sites

Terminated6Sites

2010-10-01 - 2016-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-11-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2012-06-08 - 2014-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2012-11-01 - 2019-05-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-06-01 - 2014-06-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Study ended6Sites